Kisaco Research Presents the...

2016 Selected Emerging Company Presenters

for the

European ANIMAL HEALTH INVESTMENT Forum

Taking place February 10-11, 2016 at the Royal Garden Hotel in London, UK

Kisaco Research is proud to announce the **12 selected emerging companies** voted to present at the European Animal Health Investment Forum, taking place this February in London, UK.

AbCelex Technologies Inc.

Aquilón

Causeway Therapeutics

Magnomics

Mazen Animal Health — Reinventing Animal Vaccines

Mileutis

Precision Animal Solutions

Prevtec microbia

SMB

VEROVACCINES

ViroVet Livestock Solutions

VISIT **WWW.ANIMALHEALTHEVENT.COM** FOR MORE INFORMATION

2016 SELECTED EMERGING COMPANY PRESENTER
EUROPEAN ANIMAL HEALTH INVESTMENT FORUM

MEET THE 12 EMERGING COMPANIES:

The Selection Committee, comprised of 8 influential healthcare banking and investment executives, reviewed a shortlist of 30+ emerging companies around the world during a 3-step voting process and chose these 12 companies for their innovations in diagnostics, vaccine and therapy within the animal health industry. Meet them now:

AbCelex Technologies is a Canadian biotechnology company dedicated to developing leading-edge innovations to address global food animal health and food safety challenges.

Animal Ethics Pty Ltd has developed a unique pain management and wound healing technology that will fill a large gap in the marketplace for the management of chronic wounds, wounds caused by accidents, and surgical procedures in livestock, companion animals and humans. The combination of topical anaesthetic and wound care technology, is applied to any open wound to simultaneously, alleviate pain, control bleeding, protect against infection and accelerate wound healing. The viscous gel base is designed to form a long lasting protective barrier over the wound, further prolonging the analgesic effect and reducing the risk of secondary infection. www.animalethics.net.au

Aquilón develops non-antibiotic products targeting swine digestive, respiratory and reproductive diseases that have significant economic impact on farmers worldwide. The company sources its technologies from the Spanish academia, and develops them to a significant inflection point using external providers. www.aquiloncyl.com

Causeway is a Biopharmaceutical company emerging from the University of Glasgow. Causeway's goal is to develop orthobiologic therapies for the treatment of human and animal tendinopathies. Causeway aims to deliver this cutting edge therapy to both animal and human patients, dramatically improving health and welfare.

As a university spin-off, Magnomics is the result of more than ten years of research and development in nanotechnology, physics, biotechnology and electronics, from top Portuguese academic institutions. Our proprietary technology, which includes sample preparation, amplification and detection in a small disposable cartridge, can be applied to any field where easy access to simple and fast DNA/RNA detection is required: from human health to biodefense, Magnomics' platform technology can be easily adapted to screen for multiple pathogens, alongside their respective antibiotic susceptibilities, in one go without special training or facilities.

By developing oral vaccines for diseases affecting livestock and companion animals, Mazen has the potential to significantly progress disease prevention in the Animal Health space and change existing vaccination practice.
Mazen is advancing oral vaccines that will elicit robust mucosal and systemic immune responses in a heat stable format by creating products with technology to provide low-cost antigen and vaccine production. www.mazenanimalhealth.com

Mileutis Ltd. is a clinical-stage company focused exclusively on developing and commercializing natural and novel peptides for animal and human health. Mileutis' technology consist of a biological, safe, residue free compound (casein hydrolysate) which was found to be effective in a number of randomized, case-controlled clinical studies for the management of mastitis and milk enhancement. www.mileutis.com

Precision Animal Solutions, LLC was founded by two veterinarians with a combined 35 years in the animal health business. Our core technology is the ability to monitor individual animal behavior and transform these data into actionable information to improve animal management.
www.precisionanimalsolutions.com

Prevtec Microbia specializes in developing biological products, specifically alternatives to antibiotics. The firm's first commercial product, Coliprotec F4, a swine E coli vaccine, has been sold across Canada since 2008.
Prevtec Microbia was recently awarded Animal Pharm's best new product for food-producing animals.

SMB enables diagnostic answers "Where you need them - When you need them" in the form of "Add sample – Read result" technology based on polymer microfluidic lab-on-a-chip cartridges and small table top instruments developed specifically for the veterinary industry. The products deliver an unprecedented accuracy, precision and reliability for a POC application and can be used in both the clinic and on the farm.

VEROVACCiNES developed a novel vaccine technology that applies defined pathogen components ('subunits'). The technology solves several drawbacks of current subunit vaccines like low efficacy and high cost of goods by providing full protection and being highly cost effective. VEROVACCiNES which is yet to be founded, already has an animal vaccine pipeline of 5 candidates in various stages. In addition, it has access to public, refund-free financial support covering 50% of the investment needed after its foundation.

ViroVet is an emerging Belgium-based biotech company focusing on the discovery and development of innovative virus control solutions for livestock. The strategy of ViroVet is to provide livestock solutions that can be used together, alone or in combination with existing vaccines and biosecurity, in order to provide producers and national governments with a multi-faceted arsenal of virus control weapons against endemic and epizootic viral diseases. Antiviral drug technology, together with novel vaccination platforms are currently under development to meet the needs of the production animal industry worldwide.

Join us at the **European Animal Health Investment Forum** on February 11th to watch the chosen **12 emerging companies present during 4 Dragon's Panels**, which feature 3 industry veterans with extensive experience in M&A and early stage funding.

THANK YOU TO THE 2016 SELECTION COMMITTEE

Charles Hoare
Head of Global Healthcare
COMMERZBANK

Maarten Goossens
Principle
ANTERRA CAPITAL

Claude Kaplan
Managing Director
SINOVET

Ashwin Pai
SVP Healthcare Investment Banking
JEFFERIES INTERNATIONAL

Dr. Michael Hemprich
Head of Business Development
IDT-BIOLOGIKA AND PARTNER VET VENTURE CAPITAL INC.

Dr. Paul Dick
President
PAUL DICK & ASSOCIATES LTD.
and Managing Partner and President at **VET VENTURE CAPITAL**

Ronan Molloy
President
INNOVATION STOCKYARD

SPEAKER FACULTY: ANIMAL HEALTH INDUSTRY LEADERS

Richard DeLuca
Executive Vice President and President
MSD ANIMAL HEALTH

Clinton Lewis
Executive Vice President and President of International Operations
ZOETIS

Joachim Hasenmaier
Member of the Board of Managing Directors, Corporate Board Divisions Animal Health and Consumer Health Care
BOEHRINGER INGELHEIM

Dr. Dirk Ehle
Head of Bayer Animal Health
BAYER

Thomas Zerzan
Chief Commercial Officer and Head of Global Commercial Development
MERIAL

MEET THE DRAGON'S PANEL

4 Dragon's Panellists will reflect their experience in M&A and early stage funding by posing the most appropriate – and sometimes controversial – questions to each emerging company to ensure that each panel addresses the interests of the audience whilst allowing for objective decision-making.

Marcel Lacaze
PERMIRA

Marcel joined Permira as a Principal in 2014 and focuses on the healthcare sector. Prior to joining Permira, Marcel worked for Novartis leading the M&A activities for Novartis Consumer Health, Vaccines & Diagnostics. Prior to that he spent eight years in investment banking working for Lazard and Merrill Lynch.

Marie-Paul Lachaud
Head of Program Management Europe
ARATANA THERAPEUTICS

Marie-Paul Lachaud, DVM is Head of Program Management Europe at Aratana Therapeutics. Her responsibilities include coordinating the process leading to regulatory approval by the European Medicines Agency for Aratana's products targeted at unmet medical needs in cats and dogs.

Sam Al-Murrani
BABYLON BIOCONSULTING LLC

Dr. Sam Al-Murrani, CEO, Babylon BioConsulting LLC, a human and animal health-based consultancy firm specializing in pre-revenue and early stage valuations of Animal Health and Biotech companies and providing clients with investor outreach, due diligence, business development and intangible asset management and valuation services.

Rob Readnour
Senior Director of Pharmaceutical Science and Technology
ELANCO ANIMAL HEALTH AT ELI LILLY

Dr. Readnour is an experienced senior leader with a proven track record of moving products from discovery through full commercialization. Dr. Readnour received his doctorate in Analytical Chemistry from University of Illinois in 1990 and subsequently joined Eli Lilly and Company as a senior analytical chemist in Elanco Animal Health product development.

Confirmed Partners:

zoetis · MERIAL · MSD Animal Health · GHO Capital · Cyton Biosciences a knoell company · KLIFOVET AG · Boehringer Ingelheim · Catalent · IDT · vetnosis

2016 SELECTED EMERGING COMPANIES PRESENTER
EUROPEAN ANIMAL HEALTH INVESTMENT FORUM

AbCelex Technologies Inc.



"We are most excited for the opportunity to showcase our capability in providing solutions to mitigate pathogens implicated in poultry and other livestock that are not adequately addressed by current methods/technologies. Furthermore, to meet with prospective strategic investors and partners to fund and advance our pipeline of products."

Dr Saeid Babaei
President and CEO

About the Speaker:

Dr. Babaei's track record includes over 20 years of academic and corporate experience across few industries mainly within biotechnology sector. He is currently President and CEO at AbCelex Technologies, a Canadian biotechnology company specializing in discovery, development and commercialization of technologies for food safety and animal health. Previously, he was the VP of business development at Aptose Biosciences, where he was responsible for product and technology in- and out-licensing, strategic planning and investor relations. Dr. Babaei holds a PhD and an executive MBA, both from the University of Toronto. He has authored over 50 publications including research papers, conference presentations and patents. He currently serves as Chairman of the Board of Directors of BriaCell Therapeutics, a clinical stage immuno-oncology company listed on TSX-V.

AbCelex Technologies is developing a line of innovative non-antibiotic, non-hormonal protein-based feed additives for elimination or significant reduction of zoonotic pathogens transmitted through consumption of livestock meat. AbCelex's antibody-based platform technology provide several critical advantages over conventional approaches including significantly lower cost of production, greater stability, and ability to better access the target due to their small size. These advantages, allow AbCelex to explore a promising pre-harvest intervention strategy that is practical, effective, safe and low cost in controlling Campylobacter and Salmonella in broiler production. A distinctive feature of our approach is the ability to develop targeted products against wide variety of pathogens, avoiding development of resistance that commonly develops in response to use of antibiotics.

AbCelex Technologies (www.abcelex.com) is a Canadian biotechnology company with a mission is to address food safety and livestock health issues through development and commercialization of targeted protein feed additives that are safe, effective, and economical.

AbCelex has access to a number of proprietary technology platforms based on a novel class of binding proteins naturally produced by the immune cells of camelid family animals. NanoCelex™—the Company's proprietary platform technology enables target discovery, as well as identification, isolation, and engineering of lead targeted proteins. The nanoCelex platform enables AbCelex to quickly move through discovery and development to efficiently commercialize novel protein fragments for many animal health applications. A distinctive feature of our approach is the ability to develop targeted products against wide variety of pathogens, avoiding development of resistance that commonly develops in response to use of antibiotics.

One achievement in the Animal Health space:

Demonstrating that our platform technology can address issues of wide variability of the effect of our product against zoonotic pathogens and therefore, showing cross-reactivity among different strains of these pathogens. In addition, we have demonstrated the ability to produce our targeted protein in a probiotic system as desired by the industry partners without compromising effectiveness.

Biggest opportunity in the Animal Health industry?

To take advantage of advanced techniques in molecular biology, bioinformatics and genomics to develop a targeted but yet low cost and safe products for animal health and food safety.

One thing we aim to change and/or improve the Animal Health industry?

To overcome antibiotic resistance with safe, targeted protein products and to adopt new and advanced technologies from other healthcare sectors in the Food Animal Industry.

About the Speaker:

Allan Giffard is the Co-Founder and Managing Director of Animal Ethics Pty Ltd. He has a successful entrepreneurial background specializing in the animal pharmaceutical industry. Allan has been responsible for the development, and commercialization, of some of Australia's most successful animal health/welfare products. His experience includes:

- Developed & commercialized world-first topical pain relief product for livestock.
- Co-inventor of 52 patents granted globally, for pain management and wound care technology, including the USA and EU.
- Facilitated the finance, research/development, registration and marketing of veterinarian products for both companion and farm animals.
- Advised international retailers on the impact and management of their Corporate Social Responsibility programs, regarding improved welfare of livestock.

"We are most excited for the opportunity to present our technology to industry leaders and potential investors that can provide assistance to accelerate our objectives to commercialise the technology globally."

Allan Giffard
Co-Founder and Managing Director

Animal Ethics Pty Ltd has developed a unique pain management and wound healing technology that will fill a large gap in the marketplace for the management of chronic wounds, wounds caused by accidents, and surgical procedures in livestock, companion animals and humans. The combination of topical anaesthetic and wound care technology, is applied to any open wound to simultaneously, alleviate pain, control bleeding, protect against infection and accelerate wound healing. The viscous gel base is designed to form a long lasting protective barrier over the wound, further prolonging the analgesic effect and reducing the risk of secondary infection.

The technology (Tri-Solfen™) was initially developed for use in livestock, to manage the pain and bleeding associated with invasive surgical procedures such as tail docking, castration, breech surgery and disbudding. It is commercially proven and highly successful, with over 50 million livestock in the Australian market treated to date. Extensive independent studies by Sydney University and the CSIRO in a number of livestock species indicate that the onset of wound anaesthesia is very rapid and there is evidence of a significant ongoing analgesic effect 24 hours post application.

Key Advantages of the technology include:-
- Market Impact: proven, safe, practical and cost efficient.
- Social Impact: improved animal welfare outcomes will significantly reduce concerns raised by retailers, consumers and animal welfare groups regarding routine surgical procedures, and provide a solution for major stakeholder's animal welfare policy dilemmas.
- Reduction of antibiotic use in livestock: antiseptic agents within the formulations and the proven wound healing properties, will potentially replace routine antibiotic applications after surgical procedures are performed in livestock.

One achievement in the Animal Health space:

As an organisation Animal Ethics's technology was recently selected by the Australian Government Research & Development Corporation and the Australian Cattle, Pig, Sheep and Alpaca Industries, as the most important veterinarian medicine (number 1 priority) for extension of use for all livestock species.

Biggest opportunity in the Animal Health industry?

Currently over one billion surgical procedures are performed annually on food producing animals globally. The biggest opportunity is to provide a proven, practical and cost efficient technology that will improve animal welfare outcomes, and reduce the application of routine antibiotics after these procedures are performed. This will not only offer a significant market opportunity, but will also create a significant social impact for all stakeholders.

One thing we aim to change and/or improve the Animal Health industry?

To globally assist livestock industries, farmers and veterinarians to improve animal welfare outcomes by providing a proven, safe, practical and cost efficient technology. This technology mitigates the pain and stress associated with routine surgical procedures, and accidental trauma, whilst simultaneously creating a positive proactive animal welfare outcome.

About the Speaker:

Molecular Biologist PhD, after 10 years of academic research in Spain and US shifted to the pharmaceutical industry in 1997 to play various managerial roles in project management and business development in the leading spanish company Almirall. In 2001 left Almirall to participate in the creation of the first biotech company spun-off from the University of Barcelona, Advancell, and became its first CEO. In December 2008 left Advancell to create his current company Spherium Biomed, a hands-on incubator for early stage biomedical projects. He has served as interim first executive in ERAbiotech, TCDPharma and Archivel Farma, and serves as Director of the Board in several biotech companies in Spain. He is one of the founders of the Catalan Association of Biotech companyies (CataloniaBio). Besides his role as CEO in Spherium, he is currently Executive President in the veterinary company Aquilón Cyl SL, spin-off from Spherium and the Universidad de León, recently recognized by the "Cinco Dias" award to the best innovative project linked to the university in Spain.

"We are most looking forward to sharing our innovative business model and portfolio with potential international investors and industrial partners at the European Animal Health Investment Forum."

Luis Ruiz Avila
CEO

Aquilón develops non-antibiotic products targeting swine digestive, respiratory and reproductive diseases that have significant economic impact on farmers worldwide. The company sources its technologies from the Spanish academia, and develops them to a significant inflection point using external providers. In the digestive field Aquilón is developing the first universal vaccine to swine dysentery (AQ1201), and a live bacteria product (AQ1202). AQ1201 is based on 10-year experience pioneered by Aquilon scientist on autovaccine use, and is undergoing regulatory controlled efficacy trial under EMA's supervision. AQ1202 is a unique, patent protected proprietary product that has already shown potential as a fully substitutive of current standard practices with a significant reduction of management costs (including antibiotic cost) to manage newborn piglet dysbiosis. In the respiratory field Aquilón is developing a novel antigenic composition to reduce clinical signs and increase productive parameters in animals with disease caused by bacteria of the pasteurellaceae family, such us Pasteurella multocida, Actinobacillus pleuropneumoniae, Mannheimia haemolitica, Haemophilus parasuis and other bacteria causing important respiratory diseases to cattle, swine and avian species. This product, coded AQ1203, has an enormous potential as an add-on antigen (to increase efficacy, broaden claims and prolong IP), based on its broad scope. The fourth product in the pipeline AQ1401 targets reproductive issues. It is a breakthrough diagnostic method for Swine brucellosis. This diagnostic has the potential to become the international standard since it may reduce significantly the false positive rates of the current available methods.

One achievement in the Animal Health space:

Aquilón is the first animal health company spun-off from the Spanish University system to receive significant venture capital investment and to be awarded the "Cinco Dias Innovation Company Award" in 2014, together with Novartis and Cosentino.

Biggest opportunity in the Animal Health industry?

Current regulatory and environmental pressure against antibiotic usage, combined with changes in animal welfare regulations in intensive production make it urgent to develop new products to increase animal productivity with methods that are real alternatives to antibiotics and classic pharmacological drugs. Cost-effective, broad spectrum vaccines, probiotics and improved diagnostics based on biological approaches are thus a huge opportunity.

One thing we aim to change and/or improve the Animal Health industry?

Delivering the first universal vaccine to swine dysentery.

2016 SELECTED EMERGING COMPANIES PRESENTER
EUROPEAN ANIMAL HEALTH INVESTMENT FORUM

CAUSEWAY THERAPEUTICS

"We are a new company, attending this event represents a great opportunity to raise awareness of EquiMiR™ and engage with potential investors who can help take Causeway to the next level of growth and value. Identifying partners who share our vision for Causeway Therapeutics as a global biopharmaceutical company delivering cutting edge targeted therapies for the treatment of human and veterinary diseases. Our team are also excited to meet the other emerging companies at this event. At Causeway we never miss a chance to learn from the experiences of other high growth companies."

Yvonne Davies
CEO

About the Speaker:

Yvonne has 11 years commercial and technical business development experience in start-ups, university spin outs and blue chip companies including: Thin Film Centre, Stirling Medical Innovations Ltd, Curtis Fine Paper Ltd and the Universities of Strathclyde, St Andrews and Glasgow. Yvonne also co-Founded AccuNostics Ltd where they raised £4 M investment to develop self-monitoring blood glucose (SMBG) systems for diabetes. Yvonne also co-founded Sensor Innovations Ltd, which is a vehicle for assisting companies and Universities to successfully commercialise their IP.

Causeway is a Biopharmaceutical company emerging from the University of Glasgow. Causeway's goal is to develop orthobiologic therapies for the treatment of human and animal tendinopathies. Landmark work by our research team described for the first time a molecular mechanism that causes tendinopathy in human and animal patients. Understanding the disease at the molecular level allowed our scientists to create EquiMiR™, a therapy targeting not only the collagen dysregulation seen in the disease but also associated inflammation and pain. Causeway aims to deliver this cutting edge therapy to both animal and human patients, dramatically improving health and welfare. To achieve this Causeway has brought together veterinary and human orthopaedic specialists along with leading biomedical scientists to pursue a common goal of delivering an innovative and effective therapeutic to transform the treatment of soft tissue diseases.

One achievement in the Animal Health space:

One of our main achievements has been creating a strong working collaboration with a world leading veterinary centre at Texas A&M University. This has resulted in a clinical trial of EquiMiR™ for the treatment of tendinopathy in horses. This trial will yield unparalleled clinical data, defining molecular changes in disease progression, radiographic improvements in tendon structure and state of the art clinical measurements of tendon function.

Biggest opportunity in the Animal Health industry?

The molecular mechanism that leads to tendinopathy is conserved in all mammalian species, meaning that the active pharmaceutical product used in EquiMiR™ will be equally effective in other species, including companion animals such as dogs and cats. Our aim is to develop EquiMiR™ for the treatment of other species bringing this innovative therapy it to broadest possible range of animal patients.

One thing we aim to change and/or improve the Animal Health industry?

We are focused on bring EquiMiR™ to the market, which will represent major break through in the treatment of tendinopathy in horses. Our company's vision is to produce safe and effective medicines through the understanding of disease processes at the molecular level.

2016 SELECTED EMERGING COMPANIES PRESENTER
EUROPEAN ANIMAL HEALTH INVESTMENT FORUM

MAGNOMICS
NANOTECH FOR LIFE SCIENCES

> *"There is always a great sense of community in animal health events, which make them a pleasure to attend. It is also exciting to have this event taking place in Europe, our home turf, bringing together entrepreneurs, industry and investors – it is always a rare opportunity to have all these people in the same room."*

João Pereira
CEO

Fast and portable solutions are the future of diagnostics. The dawn of personalized medicine and the increase in antibiotic resistant bacteria demand a paradigm shift, from a rigid, laboratory-centered analysis pipeline to a flexible, distributed model, where the diagnosis occurs on site in a time efficient manner. Magnomics is at the forefront of this new paradigm by developing and commercializing a fully portable, self-contained in-vitro diagnostic device, placing itself as a global reference within the field of lab-on-chip technologies.

As a university spin-off, Magnomics is the result of more than ten years of research and development in nanotechnology, physics, biotechnology and electronics, from top Portuguese academic institutions. Our proprietary technology, which includes sample preparation, amplification and detection in a small disposable cartridge, can be applied to any field where easy access to simple and fast DNA/RNA detection is required: from human health to biodefense, Magnomics' platform technology can be easily adapted to screen for multiple pathogens, alongside their respective antibiotic susceptibilities, in one go without special training or facilities.

Magnomics first product will focus on the detection of bovine mastitis, an inflammation of the milking cow mammary gland, whose treatment depends on the bacteria involved. The company expects to complete its first prototype in early 2016, after which a series A funding round will be required for commercialisation.

About the Speaker:

João Pereira (CEO) finished his degree in Electronics Engineering in 2005, from IST, Lisbon, and received his PhD in 2010 in Brain imaging, from the University of Cambridge, United Kingdom. João worked as a business analyst at McKinsey & Company in 2005; was the co-founder of two angel funded start-ups in the United Kingdom from 2007 to 2012: a web 2.0 application, and a high-tech telecommunications (ultra-small antenna technology) company. He was also a Research Fellow at the School of Clinical Medicine of the University of Coimbra between 2012 and 2014, focusing on medical signal processing and lecturing biomathematics, statistics and automated learning. João is the author of several peer-reviewed papers in high impact scientific journals and is the founding member of the Laboratory of Biostatistics and Medical Informatics. He received several innovation awards in the United Kingdom, including Cambridge University, Downing College, Imperial College and London Business School entrepreneurship awards, and was nominated one of most promising young entrepreneurs in the UK in 2010 by "The Spectator" magazine. He is a founding partner and an executive board member of Magnomics since its inception.

One achievement in the Animal Health space:

Winning the 2015 Innovation Award at the Kansas City Animal Health Investment Forum was certainly a key highlight.

Biggest opportunity in the Animal Health industry?

Within the diagnostics space, where Magnomics operates, fast, portable and easy to operate molecular diagnostic solutions are a growing opportunity, which has seen fast growth due to market creation due to a clear pull from end users tired of waiting days for the results of bacterial detection analyses.

One thing we aim to change and/or improve the Animal Health industry?

One thing we aim to change and/or improve the Animal Health industry?

2016 SELECTED EMERGING COMPANIES PRESENTER
EUROPEAN ANIMAL HEALTH INVESTMENT FORUM

MAZEN ANIMAL HEALTH
REINVENTING ANIMAL VACCINES

"One thing Mazen is trying to achieve is the increased health of animals through better disease management, in order to help our industry improve protein production, lower costs by reducing losses due to disease, and decrease medication burden by vaccinating animals with low cost, easy to administer oral vaccines."

Jennifer A. Filbey, Ph.D.
CEO

About the Speaker:

Dr. Jennifer Filbey serves as the CEO of Mazen Animal Health. Throughout her career she has focused on new company formation and leadership, business strategy, business development and licensing expertise to companies involved in the life sciences. Her experience encompasses both startup and existing drug delivery / pharmaceutical organizations, transforming the strategic direction to enhance the value of the companies. Her involvement spans from idea generation to pre-clinical/clinical studies to commercial launch of products. Dr. Filbey brings a demonstrated ability to bridge the science and business to raise capital and bring parties together through deals.

By developing oral vaccines for diseases affecting livestock and companion animals, Mazen has the potential to significantly progress disease prevention in the Animal Health space and change existing vaccination practice.

Mazen is advancing oral vaccines that will elicit robust mucosal and systemic immune responses in a heat stable format by creating products with technology to provide low-cost antigen and vaccine production.

As an oral vaccine, there is no need for needles, syringes or trained personnel, making it much easier logistically to administer the vaccine. In addition, as a heat stable vaccine, it can be maintained and transported around the world without the requirement of the cold chain. The cost and convenience benefits make Mazen oral vaccines much more accessible, cost-effective and less cumbersome for farmers, veterinarians, and pet owners.

One achievement in the Animal Health space:

Effective protection against TGEV in swine was demonstrated in a challenge study, along with strong antibody responses, after oral administration of the vaccine. Early product development was accomplished through a partnership with technology collaborator, Applied Biotechnology Institute, and led to selection of the first product candidate, an oral PRRS vaccine.

Biggest opportunity in the Animal Health industry?

With the growing human population we are witnessing a constantly increasing demand for protein and pressure on protein production worldwide. These protein demands are coupled with consumer and regulatory requirements to decrease in medications used to treat diseases commonly occurring in high-density animal production. A cost-effective solution to decrease disease in high-density animal production, such as oral vaccination, would enable the farmer to increase production while managing costs.

What are you most excited about for the event?

Mazen's oral vaccines offer the potential to significantly and positively impact animal health and production – we need resources to make it happen. The EU Animal Health Investment Forum offers an opportunity to gain visibility and momentum at this critical stage of company development from a global group of interested stakeholders who cannot only contribute resources, but also different perspectives on moving this technology to a commercial reality.

2016 SELECTED EMERGING COMPANIES PRESENTER
EUROPEAN ANIMAL HEALTH INVESTMENT FORUM

Mileutis

"We aim to revolutionize the way current treatments and management are performed in the dairy industry and replace them with alternatives that are natural and cost-effective."

David Javier Iscovich
CEO

Mileutis Ltd. is a clinical-stage company focused exclusively on developing and commercializing natural and novel peptides for animal and human health. Mileutis' technology consist of a biological, safe, residue free compound (casein hydrolysate) which was found to be effective in a number of randomized, case-controlled clinical studies for the management of mastitis and milk enhancement. Mastitis is the major cause of milk production loss in the modern dairy farm, primarily treated by antibiotics. Currently, there is no FDA-approved non-antimicrobial, non-genetically modified organism (GMO) intramammary pharmaceutical to aid veterinarians in the treatment of mastitis and milk enhancement. Concerns on antimicrobial resistance led authorities around the world to control antimicrobial use for animal health, and several countries have already restricted their use for prevention of mastitis and as growth promoters. Mileutis' technology will revolutionize the way veterinarians treat a wide range of diseases, can replace antibiotic use in a number of key indications and will deliver value for veterinarians, dairy barns and dairy cows by adding revenues via higher production, increased quality of milk and more efficient treatment. Mileutis' products, were developed following receipt of a worldwide exclusive license of an innovative technology, whose first patent was granted to the world renowned Agricultural Research Organization, Volcani Center, Israel.

About the Speaker:

Mr. Iscovich has over fifteen years of experience in the life science industry, holding senior positions in business development and in the areas of marketing, M&A and strategy. Mr. Iscovich, co-founded Mileutis Ltd., and has been Vice President of Business Development since founding Mileutis Ltd. He has led the company to the completion of a number of successful collaborations. Mr. Iscovich is a co-inventor of patent families related to Mileutis' technology.

Since 2012, he has been the Chief Executive Officer of Mileutis. Prior, Mr. Iscovich served in the Antitrust Authority of Israel, where he was responsible for the assessment of multibillion M&A of leading companies in the health, chemical and infrastructure markets. Mr. Iscovich holds a Bachelor degree in Economics and International Politics, and an MBA from the Hebrew University of Jerusalem.

One achievement in the Animal Health space:

Developed a line of safe, cost effective, environmentally friendly products that will have a significant impact on the way modern dairy farms treat and manage dairy cows, which will reduce agony to dairy cows and lead to a healthier production. The line of products will benefit veterinary dairy management by increasing productivity and specifically by efficiently making a wider environmental impact of production systems.

Biggest opportunity in the Animal Health industry?

The Animal Health Industry faces many opportunities in a number of different fields. In the dairy industry, the development of a non-antibiotic and residual free solution, which will enhance productivity via cost-effective farm management, is strongly required by the dairy industry.

What are you most excited about for the event?

Introduce to the animal health community a solution that is safe, novel and unique, that will have a substantial impact on dairy management.

About the Speaker:

Dr. Brad White received his Doctor of Veterinary Medicine degree from the University of Missouri-Columbia and worked for six years in a mixed animal practice in southeast Missouri. He is co-founder and currently serves as CEO for Precision Animal Solutions, a company that uses remote monitoring to identify cattle wellness. He is also currently on faculty at the Kansas State University College of Veterinary Medicine. Dr. White is also involved in several professional organizations including the American Veterinary Medical Association, Kansas Veterinary Medical Association, American Association of Bovine Practitioners, and is currently serving on the executive board for the Academy of Veterinary Consultants.

"Our research and development work has led to creation of the Remote Early Disease Identification (REDI) system that has been shown to identify calves with BRD early in the disease process."

Brad White
Founder

Precision Animal Solutions, LLC was founded by two veterinarians with a combined 35 years in the animal health business. Our core technology is the ability to monitor individual animal behavior and transform these data into actionable information to improve animal management. Accurate disease diagnostics based on objective data promotes judicious antimicrobial use, efficient labor utilization, and animal welfare. The overarching commercialization goal is to create a series of software tools providing information to facilitate knowledge-based animal health and management decisions. The initial focus is using our remote early disease identification (REDI) system to accurately and efficiently identify bovine respiratory disease (BRD) in beef cattle. While BRD is the initial focus, these novel disease detection algorithms can also be applied to other production systems (e.g. disease detection in dairy cattle), and the objective behavioral monitoring can facilitate inventory management, labor allocation, and animal welfare decisions.

Biggest opportunity in the Animal Health industry?

The biggest opportunity in the Animal health industry is to transform raw data into actionable information to influence health and management decisions. We feel our technology and platform allows collection of a unique data stream which then can be used to improve diagnostic ability and optimize the decision process.

What are you most excited about for the event?

We are excited to discuss the opportunities for application of our technology in new environments and learn from other animal health professionals.

One thing we aim to change and/ or improve the Animal Health industry?

Our company is focused on providing actionable information and our current area of emphasis is improving field diagnostic ability based on behavioural data. We believe improved diagnostics can facilitate judicious antimicrobial use, improve cattle welfare, and promote efficient labor allocation.

About the Speaker:

Michel Fortin has been the chief architect of Prevtec Microbia's business and financial strategies since 2005. He has successfully closed multiple rounds of financing and negotiated intellectual property agreements, research contracts and strategic partnerships. Mr. Fortin leads Prevtec Microbia's product development, marketing and distribution strategies for world markets.

"The European Animal Health Investment Forum is a good opportunity for us to meet with financial investors and pharma representatives. Our first commercialized vaccine is commercialized in Canada and in the European Union so it is important for Prevtec Microbia to be positioned as a leading biotech company in both markets."

Michel Fortin, C.P.A., C.A.
President and CEO

Prevtec Microbia is a private Canadian biotechnology company developing biological products for the prevention of diseases in food animals. The Company's mission is to develop and market alternative products to antibiotics, to offer sustainable solutions that contribute to improving animal health, performance, production and food safety. Prevtec Microbia's first commercial product, Coliprotec®F4, a swine E. coli vaccine, has been sold across Canada since 2008. In March 2015, Prevtec Microbia was granted a market authorization for Coliprotec F4 in the European Union and the product is distributed by Elanco, the second largest animal health company in the world.

One achievement in the Animal Health space:

Prevtec Microbia adopted a business platform that allowed it, with the support of external partners, to bring a scientific discovery to commercialization, by coordinating the research stages of development, registration and manufacturing while maintaining IP connected to this discovery. This approach greatly contributes to reducing the risks associated with new product development. Prevtec Microbia is now working to repeat these steps for new products with even more agility, speed and efficiency. As the CEO since the inception of Prevtec Microbia, I was leading the capital funding of the Company. A total of CAD $24 million was raised between 2008 and 2015 leading to complete the full cycle of product development. Today we have three products on the market, on four continents, in 33 countries.

Biggest opportunity in the Animal Health industry?

- Demand for safe protein and global hunger (9 B population by 2050);
- Global awareness of antibiotic resistance and global response to supervise, regulate or ban antibiotics to promote growth in food animals;
- Trends in a consolidated Animal Health Industry: renewed interest from pharma to scout new technologies from innovative biotech companies;
- Financial markets and private equity funds eyeing the Animal Health market.

One thing we aim to change and/or improve the Animal Health industry?

We will aim to be at the forefront and a key source of new ideas and innovations in the industry and we would like the Animal Health Industry to be a vital and dynamic place to do business.

About the Speaker:

Starting and developing a number of hi-tech start-up companies combined with analytical skills acquired as a management consultant and experience from large companies, has given me a unique perspective on how to develop companies / organizations to achieve sustained high-level growth over an extended period. I have also developed a strong understanding within technology-based products of what is viable in the market place, how to build "Go to market" strategies and execution of such strategies.

"SMB wants to bring advanced diagnostic capabilities into the hands of users in such a way, that they without training can perform tests where and when they need them in order to improve patient outcome, increase earnings and achieve a better business flow."

Ole Kring
CEO, Founder and Owner

SMB enables diagnostic answers "Where you need them - When you need them" in the form of "Add sample – Read result" technology based on polymer microfluidic lab-on-a-chip cartridges and small table top instruments developed specifically for the veterinary industry. The products deliver an unprecedented accuracy, precision and reliability for a POC application and can be used in both the clinic and on the farm. To date SMB has launched 2 platforms enabling ELISA, Turbidity, Hemagglutination and Viscosity dry chemistry assay formats with sensitivity down to below ng/mL and the ability of up to 6x multiplexing on one cartridge. SMB is currently working on developing further two platforms aimed at Clinical Chemistry and Molecular Dx with +20x multiplexing capability with the aim of having a product line that truly will disrupt what tests can be done in the clinic or at the farm as compared to that of the service laboratory.

As a company SMB has experienced 31% CAGR in revenues over the last 8 years and the company has been profitable since 2012. We pursue a "Nespresso business model" and as such SMB have sold +7.000 instruments and built a state of the art development and production facility in Copenhagen, where we currently produce more than 500.000 cartridges and 1.500 instruments per year. SMB is now ready to accelerate its growth significantly and are exploring strategic options to achieve this objective.

One achievement in the Animal Health space:

Developing and market a product line especially designed for the need of the veterinarian. A product line based on cutting edge technology, that enables the veterinarian to diagnose patients in relation to time critical diagnostic issue where and when they need to. A product line that is based on a platform that continually allows SMB to offer new tests that increases the diagnostic capability of the veterinarian.

Biggest opportunity in the Animal Health industry?

Within the diagnostic space the biggest opportunity is to move assays from the Service laboratory to Point of Care combined with offering novel solutions for existing problem, both within the companion and production animal space. Examples of this could be IDEXX new test for Hook-, Ring- and Roundworm in dogs or "Open Cow" product for the cattle industry. Both financial opportunities of $200+ million within a 5-year span according to IDEXX.

What are you most excited about for the event?

For SMB the key attraction of the event is the opportunity to meet up with companies focused on the veterinary industry who could prove essential to exploring the strategic alternatives for significantly increasing our current revenue growth of 30% CAGR over the next 5-7 years.

2016 SELECTED EMERGING COMPANIES PRESENTER
EUROPEAN ANIMAL HEALTH INVESTMENT FORUM

VEROVACCiNES

> *"I am looking forward to meet a multiplicity of investors from the animal health field. Since the majority of animal health investors are US-based, this is a challenge from the European point of view. It is a distinction being selected for a presentation at the conference. It will give us the opportunity to spread the word about the upcoming VEROVACCiNES. This will definitely facilitate matchmaking with potential investors."*

Hanjo Hennemann, Ph.D.
CEO

About the Speaker:

Hanjo Hennemann is currently preparing the spin-out of the veterinary vaccine company VEROVACCiNES from the University of Halle-Wittenberg, Germany. From 2007 to 2014 he founded and headed the biopharmaceutical company Nexigen GmbH in Bonn/Cologne, Germany as CEO/CSO, developing cell-permeable peptide drugs for indications in oncology. From 2002 to 2007 he was principal investigator at the research center caesar, Bonn, Germany where he established a yeast-based discovery technology for peptide drugs, initiated drug discovery programs in in oncology and infectious diseases and founded Nexigen GmbH. Before that he had postdoctoral appointments at the University of Essen and the University of California, San Diego, USA. He was awarded an Alexander-von-Humboldt Fellowship for the post-doctoral work in the group of Prof Michael Karin (University of California, San Diego) in signal transduction and growth control. Dr Hennemann earned a diploma and doctorate in molecular genetics from the University of Bonn, Germany.

VEROVACCiNES developed a novel vaccine technology that applies defined pathogen components ('subunits'). The technology solves several drawbacks of current subunit vaccines like low efficacy and high cost of goods by providing full protection and being highly cost effective. Moreover, the VEROVACCiNES technology offers the possibility to combine different subunits and to protect vaccinees with 'combination vaccines' against several pathogens simultaneously. Manufacturing and application to the animal are safe, because the vaccines are pathogen-free. There is no need for high-containment manufacture reducing the production costs further. VEROVACCiNES novel vaccine class consists of dried, heat-killed yeast containing the pathogen components. The multimeric nature of the vaccines triggers a tripartite immune response (innate, humoral and cellular), leading to fast and full protection. The exceptional stability of the vaccines simplifies logistics significantly as a continuous cold chain is not required. This extends the usability and opens new market fields. The technology has been validated for the two general virus classes (coated and uncoated viruses) and can be broadly used with virtually every pathogen. VEROVACCiNES which is yet to be founded, already has an animal vaccine pipeline of 5 candidates in various stages. In addition, it has access to public, refund-free financial support covering 50% of the investment needed after its foundation.

One achievement in the Animal Health space:

It was a great achievement for us, when our lead candidate vaccine (against infectious bursal disease) generated full protection against the nastiest version of the virus, even after only ONE application. It should be noted, that the vaccine is an inactivated subunit vaccine and that there had been no prior prime-vaccination.

Biggest opportunity in the Animal Health industry?

New emerging pathogens and the generation of novel pathogen variants generate an increasing complex threat for animal health. To protect animals from infection requires increasing numbers of different vaccines, time-consuming vaccination efforts and thus steadily increasing costs.

One thing we aim to change and/or improve the Animal Health industry?

We want to advance the vaccine field towards efficacious and cost-effective combination vaccines.

Dr. Erwin Blomsma
Co-Founder and CEO

ViroVet is an emerging Belgium-based biotech company focusing on the discovery and development of innovative virus control solutions for livestock. The strategy of ViroVet is to provide livestock solutions that can be used together, alone or in combination with existing vaccines and biosecurity, in order to provide producers and national governments with a multi-faceted arsenal of virus control weapons against endemic and epizootic viral diseases. Antiviral drug technology, together with novel vaccination platforms are currently under development to meet the needs of the production animal industry worldwide.

About the Speaker:

Erwin Blomsma holds a Master's degree in Bioscience Engineering and a Ph.D. in Applied Biological Sciences (1995) from KU Leuven in Belgium. After post-doctoral studies at UCB he started his career at Janssen Pharmaceutica in 1996 in the Chemical Process Technology Group. In 2000 he co-founded Crystallics, a spin-off from the University of Leiden (NL) specializing in preformulation research. Crystallics was absorbed by Avantium Technologies in 2001, and he was appointed Chief Operating Officer there in 2004, playing a key role in making the company cash-positive. In 2007, Dr Blomsma joined Dr Stefaan Wera and Professor Johan Neyts as co-founder and CEO of Okapi Sciences where he was responsible for day-to-day operations, finance, legal, IT, investor relations, business development and leading the management team. From January 2014 to August 2015 he was the General Manager of Aratana Therapeutics NV in Belgium and Vice President of Aratana Therapeutics, Inc., a dual role he assumed after the acquisition of Okapi Sciences. In July 2015 he joined Aratana Therapeutics NV, Stefaan Wera BVBA and Nesya Goris as co-founder of ViroVet BVBA. In August 2015, Erwin Blomsma resigned at Aratana Therapeutics to become an independent advisor to Aratana Therapeutics until the closing of ViroVet's Series A. As of August 2015, Erwin Blomsma (Esbee BVBA) is the active CEO of ViroVet BVBA. Furthermore, Erwin Blomsma is the current Chairman of FlandersBio, a cluster organization representing over 300 biotech companies in Flanders, Belgium.

UPCOMING EVENTS

2016 SELECTED EMERGING COMPANIES PRESENTER
EUROPEAN ANIMAL HEALTH INVESTMENT FORUM

European ANIMAL HEALTH INVESTMENT Forum

European Animal Health Investment Forum

February 8-9, 2017 | London, UK
www.animalhealthevent.com

Adoptive T-Cell Therapy Congress

Adoptive T Cell Therapy Congress

March 15-16, 2016 | London, UK
www.tcellcongress.com

Plant Improvement Technologies Congress

Plant Improvement Technologies Congress

March 30-31, 2016 | Hamner Conference Center, Research Triangle, North Carolina
www.planttechevent.com

Personalized Nutrition Congress

Personalized Nutrition Congress

May 18-19, 2016 | Boston, MA
www.personalizednutrition-usa.com

Personalised Nutrition Europe

Personalized Nutrition Europe

June 22-23, 2016 | Amsterdam, The Netherlands

North American Adoptive T-Cell Therapy Congress

Adoptive T Cell Therapy Congress USA

June 29-30, 2016 | Boston, MA

Psychiatric Genomics Congress

Psychiatric Genomics

September 21-22, 2016 | Boston, MA

ANIMAL HEALTH INVESTMENT ASIA

Animal Health Asia

October 19-20, 2016

EUROPEAN MICROBIOME CONGRESS 2016

2nd Annual European Microbiome Congress

November 16-17, 2016 | London, UK
www.microbiomecongress.com

Contact Us Today at Events@KisacoResearch.com or Call Us at +44 (0)20 3696 2920.


Sarah Clayton
Managing Director


Kim Vigilia
COO


Stephen Swarray
Director of Commercial Partnerships